Nilotinib: A review of its use in chronic myelogenous leukemia

Medicine & Life Sciences

• 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide 82%
• Leukemia, Myelogenous, Chronic, BCR-ABL Positive 60%
• Imatinib Mesylate 51%
• Phosphotransferases 26%
• Philadelphia Chromosome 14%
• Genetic Translocation 14%
• Standard of Care 11%
• Oncogenes 10%
• Safety 6%
• Therapeutics 5%
• Pharmaceutical Preparations 4%

Chemical Compounds

• Nilotinib 100%
• Imatinib 85%
• Phosphotransferase Inhibitor 36%
• Safety 12%
• Pharmaceutical 10%